# Calder Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/calder-biosciences

- Industry: Biotechnology
- Headquarters: Brooklyn, US
- Website: www.calderbiosciences.com/
- Latest round: Seed (May 20, 2025)
- Investors on record: 1

## About

Calder Biosciences is a biotechnology company focused on developing innovative subunit vaccines, utilizing proprietary technology to enhance immune responses against various viral infections.Calder Biosciences Inc. was founded in 2018 and is headquartered in Brooklyn, US. The company specializes in the creation of subunit vaccines. The founder's history and any previous companies are not disclosed. Since its inception, Calder has engaged in one funding deal, with the most recent occurring on May 20, 2025, with funding from SOSV.Calder Biosciences specializes in the development of innovative subunit vaccines utilizing its proprietary 3D-Vaxlock™ technology. The core product offerings focus on vaccines designed to provide protection against respiratory syncytial virus (RSV), seasonal and pandemic influenza, and Epstein-Barr virus (EBV). By employing site-specific, covalent crosslinks within proteins, Calder’s vaccines create immunogens that maintain their most effective three-dimensional structure, thereby eliciting stronger immune responses. The company aims to serve a diverse client base that includes healthcare providers, governmental health organizations, and pharmaceutical partners across North America, Europe, and Asia. These vaccines are intended for mass distribution to health systems and clinics, ultimately benefiting the general population by enhancing public health outcomes.Calder Biosciences generates revenue through strategic partnerships and collaborations with governmental and private health organizations, focusing on the development and commercialization of its vaccine products. The transactional structure typically involves agreements where partners fund research and development in exchange for access to proprietary technology and future product royalties. Revenue is derived from milestones achieved during the vaccine development process, as well as from the eventual sales of vaccines to healthcare providers and institutions. Key products include the RSV vaccine and universal flu vaccine, which are anticipated to drive significant revenue upon market entry. The pricing strategy for these vaccines is aligned with industry standards, reflecting the high value placed on innovative solutions to global health challenges.Calder Biosciences plans to launch new vaccines targeting RSV and a universal flu vaccine in the coming years. The company is actively pursuing expansion into European and Asian markets by 2026. Recent funding from the Seed round in May 2025 will support these initiatives, allowing for continued development and market entry of their innovative vaccine solutions.

## Funding rounds

- Seed, May 20, 2025 — SOSV

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed